Loading
Protein Degradation and Inhibitors · Journal article
Journal of Nanobiotechnology · September 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical proof-of-concept study demonstrating that a nanoparticle delivery system combining a BRD4-targeting PROTAC with a PD-1 antagonist peptide achieves tumor growth inhibition and immune activation in an animal model. The work is mechanistically novel but does not constitute evidence for clinical efficacy and requires validation in larger animal studies and eventual human trials.
Preclinical in vivo study. Lung cancer cell lines in vitro and in vivo lung cancer tumor-bearing animals; no human population enrolled.. Intervention: HELD nanoparticles carrying PROTAC dBET6 and PD-1 antagonist peptide..
HELD nanoparticles achieved 89.2 ± 3.7% BRD4 protein degradation in lung cancer cells HELD enhanced CD8⁺ and CD4⁺ T cell infiltration and increased IFN-γ, IL-2, and TNF-α secretion In vivo HELD mediated synergistic lung cancer therapy with excellent tumor inhibition and minimal systemic toxicity
No human clinical data; mechanism and safety in humans are unknown In vivo HELD mediated synergistic lung cancer therapy with excellent tumor inhibition and minimal systemic toxicity
This represents early-stage research in nanoparticle design and does not yet inform clinical practice. Clinicians should not consider this validated for human use and should await preclinical optimization and clinical trial initiation before assessment.
Preclinical in vivo study in animal models demonstrating a novel nanoparticle-PROTAC combination system; no human clinical data, efficacy compared only to implied controls, and lacks direct comparison to standard therapies.
As stated by the source record.
Quoted from the source exactly as published.
This represents early-stage research in nanoparticle design and does not yet inform clinical practice. Clinicians should not consider this validated for human use and should await preclinical optimization and clinical trial initiation before assessment.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
The present lung cancer therapy encounters the difficulties including surgical trauma, drug resistance, or immune exhaustion. Increasing evidences also indicated that the monotherapy showed limited effects in lung cancer therapy. Here, we have developed a type of combination therapy system (HELD), which is constructed by encapsulating the proteolysis targeting chimeras (PROTAC) reagent targeting to Bromodomain-containing proteins 4 (BRD4), dBET6 into Poly(lactic-co-glycolic acid) (PLGA) nanoparticles, and further coating them with hybrid exosome membranes-derived from lung cancer cells and programmed death-1 (PD-1) antagonist peptide-engineered HEK 293T cells. The PD-1 antagonist peptide (PD1A) on the surface of HELD can be cleaved in the matrix metallopeptidase 2 (MMP2)-abundant environments, which is beneficial for the potential immune checkpoint blockade. Moreover, the PROTAC-loaded nanoparticle can be uptaken by the lung cancer cells effectively via the homotypic targeting effects, and resulting in 89.2 ± 3.7% BRD4 protein degradation in these cells. HELD exhibited efficient tumor accumulation, powerful BRD4 degradation, and c-Myc suppression, thereby impairing tumor proliferation. Simultaneously, HELD enhanced CD8⁺ and CD4⁺ T cell infiltration, increased IFN-γ, IL-2, and TNF-α secretion, collectively remodeling the TME. In vivo, HELD mediated synergistic lung cancer therapy and achieved excellent tumor inhibition with minimal systemic toxicity. This study demonstrates that combining PROTACs and PD-1 antagonist peptides provides a promising therapeutic strategy for lung cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.